Literature DB >> 8306284

A mouse model for calculating cross-organ beta doses from yttrium-90-labeled immunoconjugates.

T E Hui1, D R Fisher, J A Kuhn, L E Williams, C Nourigat, C C Badger, B G Beatty, J D Beatty.   

Abstract

BACKGROUND: The organs of laboratory mice used in radioimmunotherapy experiments are relatively small compared to the ranges of high-energy yttrium-90 (Y-90) beta particles. Current Medical Internal Radiation Dose (MIRD) dosimetry methods do not account for beta energy that escapes an organ. A dosimetry model was developed to provide more realistic dose estimates for organs in mice who received Y-90-labeled antibodies by accounting for physical and geometric factors, loss of beta dose due to small organ sizes, and cross-organ doses.
METHODS: The dimensions, masses, surface areas, and overlapping areas of different organs of 10 athymic nude mice, each weighing approximately 25 g, were measured to form a realistic geometric model. Major organs in this model include the liver, spleen, kidneys, lungs, heart, stomach, small intestine, large intestine, thyroid, pancreas, bone, marrow, and carcass. A subcutaneous tumor mass also was included in the model. By accounting for small organ absorbed fractions and cross-organ beta doses, the MIRD methodology was extended from humans to mice for beta dose calculations.
RESULTS: Absorbed fractions of beta energy were calculated using the Berger's point kernels and the electron transport code EGS4. Except for the tumor and carcass, the self-organ absorbed fractions ranged from 15% to 20% in smaller organs (the marrow and thyroid) to 65%-70% in larger organs (the liver and small intestine). Cross-organ absorbed fractions also were calculated from estimates of the overlapping surface areas between organs.
CONCLUSION: The mathematic mouse model presented here provides more realistic organ dosimetry of radiolabeled monoclonal antibodies in the nude mouse, which should, in turn, contribute to a better understanding of the correlation of biodistribution study results and organ-tumor toxicity information.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8306284     DOI: 10.1002/1097-0142(19940201)73:3+<951::aid-cncr2820731330>3.0.co;2-1

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  29 in total

1.  Scattered Dose Calculations and Measurements in a Life-Like Mouse Phantom.

Authors:  David Welch; Leah Turner; Michael Speiser; Gerhard Randers-Pehrson; David J Brenner
Journal:  Radiat Res       Date:  2017-01-31       Impact factor: 2.841

2.  In vivo localization of ⁹⁰Y and ¹⁷⁷Lu radioimmunoconjugates using Cerenkov luminescence imaging in a disseminated murine leukemia model.

Authors:  Ethan R Balkin; Aimee Kenoyer; Johnnie J Orozco; Alexandra Hernandez; Mazyar Shadman; Darrell R Fisher; Damian J Green; Mark D Hylarides; Oliver W Press; D Scott Wilbur; John M Pagel
Journal:  Cancer Res       Date:  2014-09-26       Impact factor: 12.701

3.  166Ho and 90Y labeled 6D2 monoclonal antibody for targeted radiotherapy of melanoma: comparison with 188Re radiolabel.

Authors:  S Thompson; B Ballard; Z Jiang; E Revskaya; N Sisay; W H Miller; C S Cutler; E Dadachova; L C Francesconi
Journal:  Nucl Med Biol       Date:  2013-12-30       Impact factor: 2.408

4.  Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model.

Authors:  John M Pagel; Aimee L Kenoyer; Tom Bäck; Donald K Hamlin; D Scott Wilbur; Darrell R Fisher; Steven I Park; Shani Frayo; Amanda Axtman; Nural Orgun; Johnnie Orozco; Jaideep Shenoi; Yukang Lin; Ajay K Gopal; Damian J Green; Frederick R Appelbaum; Oliver W Press
Journal:  Blood       Date:  2011-05-25       Impact factor: 22.113

Review 5.  Preclinical animal research on therapy dosimetry with dual isotopes.

Authors:  Mark W Konijnenberg; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-04-01       Impact factor: 9.236

6.  Construction of mouse phantoms from segmented CT scan data for radiation dosimetry studies.

Authors:  D Welch; A D Harken; G Randers-Pehrson; D J Brenner
Journal:  Phys Med Biol       Date:  2015-04-10       Impact factor: 3.609

7.  Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.

Authors:  Damian J Green; Shani L Frayo; Yukang Lin; Donald K Hamlin; Darrell R Fisher; Sofia H L Frost; Aimee L Kenoyer; Mark D Hylarides; Ajay K Gopal; Theodore A Gooley; Johnnie J Orozco; Brian G Till; Shyril O'Steen; Kelly D Orcutt; D Scott Wilbur; K Dane Wittrup; Oliver W Press
Journal:  Cancer Res       Date:  2016-09-02       Impact factor: 12.701

8.  Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.

Authors:  Johnnie J Orozco; Tom Bäck; Aimee Kenoyer; Ethan R Balkin; Donald K Hamlin; D Scott Wilbur; Darrell R Fisher; Shani L Frayo; Mark D Hylarides; Damian J Green; Ajay K Gopal; Oliver W Press; John M Pagel
Journal:  Blood       Date:  2013-03-07       Impact factor: 22.113

9.  203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection.

Authors:  Yubin Miao; Said D Figueroa; Darrell R Fisher; Herbert A Moore; Richard F Testa; Timothy J Hoffman; Thomas P Quinn
Journal:  J Nucl Med       Date:  2008-04-15       Impact factor: 10.057

10.  Effect of emaciation and obesity on small-animal internal radiation dosimetry for positron-emitting radionuclides.

Authors:  Tianwu Xie; Habib Zaidi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-07-02       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.